scholarly journals A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model

2017 ◽  
Vol 327 ◽  
pp. 65-74 ◽  
Author(s):  
Lijuan Shi ◽  
Zhihua Zhang ◽  
Lin Li ◽  
Christian Hölscher
Keyword(s):  
Cognitive Decline ◽  
Rat Model ◽  
Insulin Signaling ◽  
Receptor Agonist ◽  
Gip Receptor

scholarly journals Cannabinoid Receptor Agonist WIN55, 212-2 Adjusts Lipid Metabolism in a Rat Model of Cardiac Arrest

2020 ◽  
Vol 10 (4) ◽  
pp. 192-203 ◽  
Author(s):  
Yan Xiao ◽  
Daniel Contaifer ◽  
Weiping Huang ◽  
Jin Yang ◽  
Zhangle Hu ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Lipid Metabolism ◽  
Rat Model ◽  
Receptor Agonist ◽  
Cannabinoid Receptor

scholarly journals The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Enrique Z. Fisman ◽  
Alexander Tenenbaum
Keyword(s):  
Receptor Agonist ◽  
Therapeutic Option ◽  
Insulin Response ◽  
Glucagon Secretion ◽  
Long Term Effects ◽  
Glucose Levels ◽  
Lower Glucose ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Gip Receptor

AbstractIncretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 stimulates insulin secretion, inhibits glucagon secretion at pancreatic α cells and has also extrapancreatic influences as slowing of gastric emptying which increases the feeling of satiety. GIP is the main incretin hormone in healthy people, causative of most the incretin effects, but the insulin response after GIP secretion in type 2 diabetes mellitus (T2DM) is strongly reduced. Therefore, in the past GIP has been considered an unappealing therapeutic target for T2DM. This conception has been changing during recent years, since it has been reported that resistance to GIP can be reversed and its effectiveness restored by improving glycemic control. This fact paved the way for the development of a GIP receptor agonist-based therapy for T2DM, looking also for the possibility of finding a combined GLP-1/GIP receptor agonist. In this framework, the novel dual GIP and GLP-1 receptor agonist tirzepatide seems to be not just a new antidiabetic medication. Administered as a subcutaneous weekly injection, it is a manifold single pharmacological agent that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia favorably modifying the lipid profile. Tirzepatide and additional dual GLP-1/GIP receptor agonists that could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings. Obviously, it is too early to be overly hopeful since it is still necessary to determine the long-term effects of these compounds and properly verify the potential cardiovascular benefits. Anyway, we are currently facing a novel and very appealing therapeutic option.

Hippocampal DHCR24 down regulation in a rat model of streptozotocin-induced cognitive decline

2015 ◽  
Vol 587 ◽  
pp. 107-112 ◽  
Author(s):  
Soheila Hosseinzadeh ◽  
Maryam Zahmatkesh ◽  
Mansour Heidari ◽  
Gholam-Reza Hassanzadeh ◽  
Morteza Karimian ◽  
...  
Keyword(s):  
Cognitive Decline ◽  
Rat Model ◽  
Down Regulation

The contribution of muscarinic-receptor-mediated responses to epineurial vascular diameter at the sciatic nerve

2018 ◽  
Vol 96 (8) ◽  
pp. 855-858
Author(s):  
Chelsa Killey ◽  
Shane Cleary ◽  
Julie Orr ◽  
Jefferson C. Frisbee ◽  
Dwayne Jackson ◽  
...  
Keyword(s):  
Mean Arterial Pressure ◽  
Sciatic Nerve ◽  
Arterial Pressure ◽  
Muscarinic Receptor ◽  
Topical Application ◽  
Rat Model ◽  
Receptor Agonist ◽  
Vessel Diameter ◽  
Anaesthetized Rat ◽  
Baseline Diameter

This study used an anaesthetized rat model to directly observe changes in diameter of the vessels supplying the sciatic nerve in response to acetylcholine (10−4 M), a muscarinic receptor agonist, and atropine (10−5 M), a muscarinic receptor antagonist. Topical application of acetylcholine resulted in increases in vessel diameter (baseline: 22.0 ± 2.5 μm, acetylcholine: 28.8 ± 3.3 μm), while topical application of atropine resulted in a decrease in diameter (baseline: 26.6 ± 3.2 μm, atropine: 15.5 ± 3.6 μm) of the epineurial vessels. Mean arterial pressure was not affected by either acetylcholine (baseline: 103.8 ± 1.8 mm Hg, acetylcholine: 102.8 ± 3.2 mm Hg) or atropine (baseline: 104.0 ± 1.9 mm Hg, atropine: 105.2 ± 2.2 mm Hg). These data suggest that muscarinic-receptor-mediated responses can affect the diameter of the epineurial vessels at the sciatic nerve. In addition, muscarinic-receptor-mediated responses appear to contribute to baseline diameter of epineurial vessels at the sciatic nerve.

Sign in / Sign up

Export Citation Format

Share Document